An interventional study of Photobiomodulation and Photobiomodulation in Mild Cognitive Impairment (MCI), Mild Alzheimer Disease and Dementia, sponsored by Jun Xu. Recruiting at 1 site in China. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by Jun Xu · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 309 studies in Cognitive Dysfunction with a site in China — 143 open to participants now, 155 under way, 8 of them phase 3. Cognitive Dysfunction · China.
Among the 309 studies in Cognitive Dysfunction with a site in China, this one is the 184th largest by planned enrollment of the 190 interventional ones that give a count, is one of 45 that started in 2024, is one of 138 with no phase, reaches primary completion later than 72 of the 154 other live ones, and was the 282nd registered.
3,876 studies on the registry are indexed under Cognitive Dysfunction; 1,119 are open to participants now.
Browse Cognitive Dysfunction studies →143 of the 309 studies in Cognitive Dysfunction with a site in China are open now. Recruiting first, the newest first:
Shanghai University of Sport · Sites in China
Ages 60–80
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · Sites in China
Ages 35–80
Beijing Tiantan Hospital · Sites in China
Ages 12–70
Shanghai University of Sport · Sites in China
Ages 65+
Risen (Suzhou) Pharma Tech Co., Ltd. · Sites in China
Ages 50–85
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 753 Cognitive Dysfunction studies recruiting now, 364 (48%) set no upper age limit and 143 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 50 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
309 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 24 · Phase 3 17 · Phase 4 15
First in 2000; this study’s year is marked. 45 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 64 across 2,797 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 110 across the 190 interventional studies, 300 across the 119 observational. Of the 90 that completed or were terminated, 3 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 309 have an industry lead sponsor. The 10 most frequent:
Jun Xu is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Jun Xu has 1 study filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
34 of the studies in Cognitive Dysfunction with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT07603102Nanjing Mingzhou Rehabilitation HospitalMindfulness With Dual-Task Training in Post-Stroke Mild Cognitive Impairment | 2026-11 |
| NCT06417086ZhanYJClinical Evaluation of Acupuncture Treatment on Alzheimer's Disease in APOE e4 Carriers and Non-Carriers | 2026-11-30 |
| NCT07760415Xiangya Hospital of Central South UniversityEEG Changes and Cognitive Profiles in Sepsis Patients With Different Inflammatory Phenotypes | 2026-12-12 |
| NCT03810794Jian Pei,MDClinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease | 2026-12-30 |
Add all 34 to your calendar (.ics) → With an account.
Among the 309 studies in Cognitive Dysfunction with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if photobiomodulation therapy (PBMT) can help treat mild cognitive impairment and mild Alzheimer's disease in adults aged 50 to 85 years. It will also learn about the safety of PBMT. The main questions it aims to answer are:
Does PBMT improve cognitive function in adults with mild cognitive impairment or mild Alzheimer's disease? What medical problems do participants have when using PBMT? Researchers will compare an active PBMT device to a sham (look-alike) device that delivers no active light therapy to see if PBMT improves cognitive function.
Participants will:
Use a transcranial near-infrared light therapy device (or a matching sham device) once a day for 20 minutes, 5 days a week, for 6 months Visit the clinic for cognitive, mood, sleep, and daily-function assessments at the start of the study, at Month 3, and at Month 6 Have brain MRI scans at the start of the study, at Month 3, and at Month 6
Alzheimer's disease and its prodromal stage, mild cognitive impairment, are characterized by progressive neurodegeneration for which disease-modifying options remain limited. Photobiomodulation therapy (PBMT) delivers non-ionizing red and near-infrared light to neural tissue, where it is absorbed by cytochrome c oxidase in the mitochondrial respiratory chain. This is hypothesized to enhance ATP production, modulate reactive oxygen species and intracellular signaling, increase regional cerebral blood flow, and support neuroprotective and anti-inflammatory processes, providing the biological basis for evaluating PBMT as a non-invasive intervention in early Alzheimer's disease.
This is a single-center, prospective, randomized, double-blind, sham-controlled trial conducted at the Department of Cognitive Disorders, Beijing Tiantan Hospital, Capital Medical University. Eligible participants are randomly allocated in a 1:1 ratio to the active PBMT arm or the sham-control arm using a computer-generated randomization sequence. To preserve double blinding, the active and sham devices are identical in appearance and operation; the sham device emits visible light at a wavelength without established photobiomodulatory effect, so that neither participants nor outcome assessors can distinguish between arms. Treatment is self-administered at home according to a fixed schedule over the 6-month intervention period, with adherence monitored through device usage records and scheduled study visits.
Assessments are performed at baseline, Month 3, and Month 6 by trained raters blinded to group allocation. Beyond the clinical and neuropsychological battery, structural and functional MRI is used to examine treatment-associated changes in cortical and hippocampal volume, white matter integrity, and cerebral blood flow perfusion, supporting exploratory analysis of the candidate mechanisms above. Safety is monitored throughout via adverse-event reporting, device-related event tracking, and review of skin and nasal tolerability. Efficacy analyses compare between- and within-group change from baseline across the cognitive, neuropsychiatric, sleep, daily-function, and caregiver-burden domains, with imaging and tolerability data used to characterize the safety profile and explore possible mechanisms of action of PBMT in AD-derived MCI and mild AD.
1、Inclusion Criteria:
2、Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Use the transcranial photobiomodulation device at 810 nm once daily for 20 minutes per session, for 5 consecutive days, followed by 2 days off.
Device: Photobiomodulation
Use the transcranial photobiomodulation device at 660 nm once daily for 20 minutes per session, for 5 consecutive days, followed by 2 days off.
Device: Photobiomodulation
transcranial photobiomodulation
transcranial photobiomodulation
Mini-Mental State Examination
The Mini-Mental State Examination (MMSE) assesses orientation, registration, attention and calculation, recall, and language using 11 items. Total scores range from 0 to 30; lower scores indicate worse cognitive function and higher scores indicate better cognitive function.
Time frame: Baseline, Month 3, Month 6
Montreal Cognitive Assessment
The Montreal Cognitive Assessment (MoCA) assesses visuospatial and executive function, naming, attention, language, abstraction, delayed recall, and orientation. Total scores range from 0 to 30; higher scores indicate better cognitive function and lower scores indicate worse cognitive function.
Time frame: Baseline, Month 3, Month 6
Alzheimer's Disease Assessment Scale-Cognitive Subscale
The Alzheimer's Disease Assessment Scale-Cognitive Subscale, 11-item version (ADAS-Cog-11), assesses cognitive domains including memory, language, orientation, and praxis. The total score ranges from 0 to 70, with 0 indicating the least cognitive impairment and 70 indicating the most severe cognitive impairment. Higher scores indicate worse cognitive function. A decrease in score indicates improvement, whereas an increase indicates worsening.
Time frame: Baseline, Month 3, Month 6
Clinical Dementia Rating
The Clinical Dementia Rating (CDR) assesses cognition and daily functioning. The CDR Sum of Boxes (CDR-SB) ranges from 0 to 18; higher scores indicate greater impairment. The global CDR score ranges from 0 to 3: 0 = normal, 0.5 = questionable, 1 = mild, 2 = moderate, and 3 = severe; higher scores indicate worse outcomes.
Time frame: Baseline, Month 3, Month 6
Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) compares differences in cortical/hippocampal atrophy, white matter degeneration, and cerebral blood flow perfusion before and after treatment.
Time frame: Baseline, Month 3, Month 6
Hamilton Depression Rating Scale
The 17-item Hamilton Depression Rating Scale (HAMD-17) is a clinician-rated assessment of depression severity covering mood, anxiety, somatic symptoms, cognition, sleep, and related symptoms. Total scores range from 0 to 52; higher scores indicate more severe depression and a worse outcome.
Time frame: Baseline, Month 3, Month 6
Hamilton Anxiety Rating Scale
The Hamilton Anxiety Rating Scale (HAMA) is a 14-item, clinician-rated assessment of psychic and somatic anxiety. Total scores range from 0 to 56; higher scores indicate greater anxiety severity and a worse outcome.
Time frame: Baseline, Month 3, Month 6
Neuropsychiatric Inventory
The Neuropsychiatric Inventory (NPI) assesses behavioral and psychological symptoms of dementia across 12 domains. It measures symptom frequency, severity, and caregiver distress. The total score ranges from 0 to 144, with higher scores indicating more severe neuropsychiatric symptoms.
Time frame: Baseline, Month 3, Month 6
Pittsburgh Sleep Quality Index
The Pittsburgh Sleep Quality Index (PSQI) is a 19-item, self-rated assessment of sleep quality over the previous month across seven components. Total scores range from 0 to 21; higher scores indicate poorer sleep quality and a worse outcome.
Time frame: Baseline, Month 3, Month 6
Activities of Daily Living Scale
The 20-item Activities of Daily Living Scale (ADL-20) assesses basic and instrumental activities of daily living. Total scores range from 20 to 80; higher scores indicate greater dependence and worse functional ability, while lower scores indicate greater independence.
Time frame: Baseline, Month 3, Month 6
Caregiver Burden Inventory
The Caregiver Burden Inventory (CBI) assesses time-dependence, developmental, physical, social, and emotional burden. Total scores range from 0 to 96; higher scores indicate greater caregiver burden and a worse outcome.
Time frame: Baseline, Month 3, Month 6
Plan to share: Yes — All IPD that underlines results in a publication
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Starting 6 months after publication, all IPD and supporting information will be made available.
Access criteria: All information regarding participants' data on primary and secondary outcome measurements will be used in publication.
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.
Of 1,449 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 30 months is above that.
Counting every sponsor, half of 1,518 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jun Xu